Here's a summary of Concord Biotech's investor presentation: **Financial Highlights:** Q1FY26 revenue dipped 5% to 204 Cr, attributed to customer procurement lumpiness.

EBITDA fell 24% to 61 Cr (30.1% margin) and PAT 26% to 44 Cr.

Margins were impacted by new injectable facility expenses; adjusted EBITDA margin, however, was 37%. **Strategic Initiatives & Growth Drivers:** Commenced commercial CDMO supply to a major US customer, signaling future revenue potential.

Plans include broadening API portfolio, expanding injectable formulations, and increasing geographic reach.

Focus on operational efficiencies and leveraging new facility capacity. **Business Developments:** Acquired 75% stake in US-based Stellon Biotech for US market entry.

Formed wholly-owned Concord Lifegen for domestic sales.

Dholka facility successfully passed USFDA, EU GMP, and Russian GMP inspections. **Market Position & Competitive Advantage:** Leader in niche fermentation-based APIs, a high-entry-barrier segment.

Strength from 20+ years experience, large 1,250 m3 fermentation capacity, backward integration, and a robust 10+ product R&D pipeline. **Investor Implications:** Despite Q1 softness, strategic CDMO entry and market expansions point to positive growth potential.

Management's confidence in scaling new facility revenue and improving future margins offers a favorable outlook.